sponsored
PatientsVille.com Logo

PatientsVille

Thyroid Cancer Metastatic Medical Research Studies

Up-to-date List of Thyroid Cancer Metastatic Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Thyroid Cancer Metastatic Medical Research Studies

Rank Status Study
1 Recruiting Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer
Conditions: Poorly Differentiated Thyroid Gland Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Stage IVA Thyroid Gland Follicular Carcinoma;   Stage IVA Thyroid Gland Papillary Carcinoma;   Stage IVB Thyroid Gland Follicular Carcinoma;   Stage IVB Thyroid Gland Papillary Carcinoma;   Stage IVC Thyroid Gland Follicular Carcinoma;   Stage IVC Thyroid Gland Papillary Carcinoma
Interventions: Procedure: Computed Tomography;   Radiation: Iodine I 124;   Radiation: Iodine I-131;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Procedure: Positron Emission Tomography;   Drug: Trametinib
Outcome Measures: Iodine incorporation in thyroid cancer metastases to a predicted lesional absorbed radiation dose equal to or exceeding 2,000 cGy with the administration of =< 300 mCi RAI (Cohort B);   ORR (complete response or partial response) assessed by RECIST v 1.1 (Cohort A);   Progression free survival (Cohort A);   Proportion of patients alive following treatment with trametinib and I-124 (Cohort A);   Adequate increase defined as increasing iodine incorporation in thyroid cancer metastases to a predicted lesional absorbed radiation dose equal to or exceeding 2,000 cGy with the administration of =< 300 mCi RAI (Cohort A);   Best objective response (Cohort C);   Changes in thyroglobulin;   Incidence of toxicity assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (Cohort A);   ORR per RECIST v 1.1 criteria (Cohort B);   Proportion of patients alive without disease progression by RECIST v 1.1 criteria (Cohort C);   Proportion of patients alive without disease progression per RECIST v 1.1(Cohort B)
2 Not yet recruiting Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer
Conditions: Poorly Differentiated Thyroid Gland Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Stage IVA Thyroid Gland Follicular Carcinoma;   Stage IVA Thyroid Gland Papillary Carcinoma;   Stage IVB Thyroid Gland Follicular Carcinoma;   Stage IVB Thyroid Gland Papillary Carcinoma;   Stage IVC Thyroid Gland Follicular Carcinoma;   Stage IVC Thyroid Gland Papillary Carcinoma
Interventions: Other: Placebo;   Drug: Selumetinib;   Radiation: Iodine I-131;   Other: Laboratory Biomarker Analysis
Outcome Measures: Response rate;   Best overall response;   6-month progression free survival (PFS);   Changes in serum thyroglobulin levels;   Adverse event rate
3 Recruiting Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid Cancer
Condition: Metastatic Thyroid Cancer
Interventions: Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: Anti-Thyroglobulin mTCR PBL
Outcome Measure: Determine a safe dose of administration and determine if this approach will result in an objective tumor regression.
4 Unknown  Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer
Condition: Head and Neck Cancer
Intervention: Drug: everolimus
Outcome Measures: Efficacy;   Maximum percentage of tumor reduction;   Activity time to event endpoints;   Toxicity
5 Recruiting 177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer.
Condition: Thyroid Cancer, Medullary
Intervention: Drug: 177Lu-PP-F11N
Outcome Measures: Phase 0: Scintigraphic visualisation rate;   Phase I: Maximum tolerated dose;   Phase 0: Tumour-to-kidney radiation doses;   Phase 0: Radiation doses;   Phase 0: In vivo stability;   Phase 0: Metabolites;   Phase I: Side reactions;   Phase 1: Biochemical response;   Phase I: Morphological response;   Phase I: Tumour detection rate;   Phase I: Organ radiation doses;   Phase 1: Overall survival;   Phase 1: In vivo stability;   Phase 1: Metabolites
6 Recruiting Pioglitazone in Follicular or Follicular Variant of Papillary Thyroid Cancers
Conditions: Follicular Thyroid Carcinoma;   Follicular Variant of Papillary Thyroid Carcinoma
Intervention: Drug: Pioglitazone
Outcome Measures: Tumor response;   Decrease in serum thyroglobulin;   Toxicity
7 Recruiting Molecular Profile of Metastatic Sporadic Medullary Thyroid Cancer Patients and Correlation With Vandetanib
Condition: Metastatic Sporadic Medullary Thyroid Cancer
Intervention:
Outcome Measures: Validation of a miRNA profile;   Define any correlations between the miRNA profiles and RET, and H- and K-RAS mutations;   Define a circulating miRNA profile;   Analyze any change in circulating miRNAs;   Correlate circulating miRNA profile with the burden of disease;   Evaluate the correlation between the response to vandetanib and the patients molecular profile
8 Unknown  SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer
Condition: Medullary Thyroid Cancer
Intervention: Drug: SOM230 alone or in combination with RAD001.
Outcome Measures: Efficacy of SOM230 in patients with progressive metastatic or postoperative persistent medullary thyroid cancer;   Efficacy of SOM230 in combination with RAD001 in patients with progressive metastatic or postoperative persistent medullary thyroid cancer.;   Biochemical response;   Objective tumor response;   Overall survival;   Time to response;   Duration of response;   Safety
9 Not yet recruiting A Phase II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer
Conditions: Anaplastic Thyroid Cancer;   Thyroid Cancer
Intervention: Drug: MLN0128
Outcome Measures: Progression Free Survival;   Overall All Response Rate;   Overall Survival Rate;   Number of Participants with Serious and Non-Serious Adverse Events;   • Identification of biomarkers predictive of response to therapy with MLN0128
10 Recruiting Ceritinib (LDK378) in Mutation and Oncogene Directed Therapy in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
Conditions: Metastatic Anaplastic/Undifferentiated Thyroid Cancer;   Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
Intervention: Drug: Ceritinib
Outcome Measure: Development of Progression
11 Recruiting Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer
Conditions: Symptomatic, Aggressive, Sporadic, Unresectable, Locally;   Advanced/Metastatic Medullary Thyroid Cancer (MTC)
Intervention: Drug: Vandetanib 300 mg
Outcome Measures: Assessment of Objective Response Rate;   Assessment of Disease control rate;   Assessment of Duration of Response;   Assessment of Progression Free Survival;   Evaluation of Safety by assessment of QTc prolongations;   Evaluation of Safety by assessment of Adverse Events;   Evaluation of Safety by assessment of vital signs;   Evaluation of Safety by assessment of laboratory data;   Patient Characteristics
12 Unknown  Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer
Conditions: Thyroid Cancer;   Metastases
Intervention: Drug: TSH stimulation
Outcome Measures: the 124 I uptake after TSH stimulation;   The activity of 131I that should be administered according to each TSH stimulation method;   Radiation exposure of the blood
13 Recruiting A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer
Condition: Medullary Thyroid Cancer
Interventions: Drug: Cabozantinib (XL184) 140 mg;   Drug: Cabozantinib (XL184) 60 mg;   Drug: Placebo tablet;   Drug: Placebo capsule
Outcome Measures: Progression Free Survival;   Objective Response Rate
14 Recruiting Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study
Condition: Thyroid Cancer
Intervention: Drug: Sorafenib
Outcome Measures: Describe the clinical activity and safety profile of sorafenib in the treatment of patients with advanced thyroid cancer (metastatic or recurrent) among a selected group of patients refractory to or ineligible to radioactive iodine (RAI) therapy;   Summarize the progression-free survival (PFS) of patients with advanced thyroid cancer (metastatic or recurrent) treated with sorafenib;   Describe the occurrence and type of adverse events associated with sorafenib use in advanced thyroid cancer (metastatic or recurrent) patients included
15 Recruiting Radiolabeled Molecules for Medullary Thyroid Cancer
Condition: Medullary Thyroid Cancer
Intervention: Radiation: Lu 177
Outcome Measures: Tumour Shrinkage;   Quality of life improvement
16 Unknown  Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases
Conditions: Thyroid Carcinoma;   Metastatic Sites Lung Bone Nodal
Intervention: Other: SPECT scan
Outcome Measures: The primary outcome measure is to correlate the predicted dose from the tracer study with the actual absorbed dose measure on the therapeutic scan;   The secondary outcomes will be to assess the response at 6 months post therapy in each patient
17 Recruiting CC-486 (Oral Azacitidine) Bioequivalence Study in Patients With Solid Tumor or Hematologic Malignancies
Conditions: Hematological Neoplasms;   Non-Hodgkin's Lymphoma;   Hodgkin's Lymphoma;   Lymphoma;   Multiple Myeloma;   Acute Myeloid Leukemia;   Leukemia;   Myelodysplastic Syndromes;   Neoplasms;   Melanoma;   Breast Cancer;   Metastatic Breast Cancer;   Non-Small Cell Lung Cancer;   Small Cell Lung Cancer;   Renal Cell Carcinoma;   Glioblastoma Multiforme;   Osteosarcoma;   Sarcoma;   Thyroid Cancer;   Genitourinary
Interventions: Drug: CC-486;   Drug: Vidaza
Outcome Measures: PK- Cmax;   PK-Tmax;   PK-AUC-t;   PK-AUC-infinity;   PK- λz (Terminal Rate);   Terminal Half-Life (t½);   Apparent total clearance (CL/F);   Apparent volume of distribution  (Vd/F);   Incidence of treatment-emergent adverse events
18 Recruiting Ponatinib for Advanced Medullary Thyroid Cancer
Condition: Thyroid Neoplasms
Intervention: Drug: Ponatinib
Outcome Measures: To determine the objective overall response rate.;   Progression free survival;   Toxicity and safety;   Evaluate tumor markers and other correlative parameters
19 Recruiting A Multicenter Phase II Pilot Open Label
Condition: Thyroid Cancers
Intervention: Drug: BKM120
Outcome Measures: progression-free survival (PFS);   Objective tumor response (CR and PR);   Overall survival;   safety and tolerance of BKM120 of BKM120: monitoring and recording AE and SAE, monitoring of hematology, blood chemistry and urine values, vital signs, physical examinations, skin, cardiac assessments and mood evaluation.
20 Recruiting A Phase 1/2a Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer; Study Targeting ALK, ROS1, or TRKA/B/C
Conditions: Locally Advanced Solid Tumors;   Metastatic Solid Tumors
Intervention: Drug: Entrectinib
Outcome Measures: Phase 1: Dose-Limiting Toxicity (DLT);   Phase 1: Maximum Tolerated Dose (MTD);   Phase 1: Recommended Phase 2 Dose (RP2D);   Phase 2a: Objective response;   Plasma concentrations of entrectinib;   Progression-Free Survival (PFS);   Overall Survival (OS);   Disease Control;   Duration of Response

These studies may lead to new treatments and are adding insight into Thyroid Cancer Metastatic etiology and treatment.

A major focus of Thyroid Cancer Metastatic research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Thyroid Cancer Metastatic